Insider selling is routine at these dollar levels and does not signal fundamental deterioration. However, the pattern of multiple C-suite officers selling in the same window near all-time highs suggests insiders may view the current valuation as full. Monitor next earnings for any guidance changes or competitive developments in the liquid biopsy space.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $204.39entry
- T+1 · 7mo ago −2.06%α −1.58% · $200.17
- T+5 · 7mo ago +3.51%α +3.11% · $211.56
- T+20 · 6mo ago −1.70%α −6.66% · $200.91
- T+60 · 4mo ago +29.27%α +24.50% · $264.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite executives at Natera (President of Clinical Diagnostics and President/Chief Business Officer) sold a combined $360K in open-market sales on April 27, 2026, at $203.75 per share. This follows a broader cluster of insider selling by the CEO, directors, and other officers totaling ~$1.5M over the prior week. While the dollar amount is trivial relative to Natera's $28.6B market cap (0.0013%), the concentration of selling by senior leadership near the stock's recent highs warrants attention.
Key Financial Metrics
Key Facts
- President of Clinical Diagnostics Solomon Moshkevich sold 997 shares for $203K on April 27
- President and Chief Business Officer John Fesko sold 771 shares for $157K on April 27
- Total open-market sales in this cluster: $360K
- Prior week saw CEO Steven Chapman sell $463K and other insiders sell $680K
- Total insider selling over 7 days: ~$1.5M, or 0.005% of market cap
- Non-cash director grants of 728 shares on April 24 have zero economic impact
- Natera has 89% analyst bullish rating with $28.6B market cap
Financial Impact
Total insider selling of $360K in this cluster, $1.5M over 7 days, immaterial relative to $28.6B market cap
Risk Factors
- Insider selling cluster may indicate management sees limited near-term upside at current valuation
- No insider buying to offset selling pattern, one-sided selling by leadership
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NTRA-1777512943325 |
Track record
63 reports on NTRA
6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +6.55% at T+5 after the Oct 2, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $300.44 Now $288.48 −3.98% settles Nov 17
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $319.82 to $322.94 Now $288.48 −9.80% ▲ +0.98% +1.33% vs SPY
- Nov 10, 20266d ago S-3ASR Neutral 3/10 Entry $319.82 to $322.94 Now $288.48 −9.80% ▲ +0.98% +1.33% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $310.67 to $320.39 Now $288.48 −7.14% ▲ +3.13% +0.76% vs SPY
- Nov 5, 202611d ago 8-K Mixed 6/10 Entry $310.67 to $320.39 Now $288.48 −7.14% ▲ +3.13% +0.76% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $363.76 to $310.67 Now $288.48 −20.69% ▼ −14.59% −14.91% vs SPY
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $363.76 to $310.67 Now $288.48 −20.69% ▼ −14.59% −14.91% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $391.03 to $363.76 Now $288.48 −26.23% ▼ −6.97% −2.56% vs SPY
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $388.63 to $391.03 Now $288.48 −25.77% ▲ +0.62% −1.03% vs SPY
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $388.63 to $391.03 Now $288.48 −25.77% ▲ +0.62% −1.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers